CD8A and neoplasm: Chauvin JM and colleagues confirmed that TIGIT and PD-1 co-blockade could improve the expansion and function of circulating tumor specific CD8+ T cells and tumor infiltrating CD8+ T cells thus enhancing CD8+ T cell responses to melanoma.